Grand Pharma’s Independently Developed, Blockbuster, Globally Innovative Radionuclide-Drug Conjugate, GPN01530, Has Been Approved for Clinical Trials in the United States
R&D Centers
R&D People
Projects in Progress
Grand Pharma’s Independently Developed, Blockbuster, Globally Innovative Radionuclide-Drug Conjugate, GPN01530, Has Been Approved for Clinical Trials in the United States
The Phase II Clinical Trial in China of Grand Pharma’s Class 1 Innovative Traditional Chinese Medicine GPN01360 Successfully Reaches the Clinical Endpoint
The Phase IIa Clinical Study Conducted in China of Grand Pharma’s Global Innovative Ophthalmic Drug GPN00884 Has Completed the First Patient Enrollment
PHARMACEUTICAL TECHNOLOGY
NUCLEAR MEDICINE ANTI-TUMOR DIAGNOSIS AND TREATMENT AS WELL AS CEREBRO- CARDIOVASCULAR PRECISION INTERVENTIONAL DIAGNOSIS AND TREATMENT TECHNOLOGY
BIOTECHNOLOGY